AR-SA">B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).

被引：0
|
作者：
Grefer, J
Oertel, SH
Hummel, M
Serke, S
Reinke, P
Jonas, S
Anagnostopoulos, I
Arnold, R
Dörken, B
Riess, H
机构：
[1] Humboldt Univ, Klinikum Rudolf Virchow, Charite, Berlin, Germany
[2] Deutsches Herzzentrum, Berlin, Germany
[3] Free Univ Berlin, D-1000 Berlin, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4693
引用
收藏
页码：242B / 242B
页数：1
相关论文
共 50 条
  • [31] Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody
    Lacouture, ME
    Baron, JM
    Jani, AB
    Laumann, AE
    Soltani, K
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2005, 30 (01) : 46 - 48
  • [32] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
  • [33] An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab
    Gasdaska, John R.
    Sherwood, Steven
    Regan, Jeffrey T.
    Dickey, Lynn F.
    MOLECULAR IMMUNOLOGY, 2012, 50 (03) : 134 - 141
  • [34] Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
    Rouzière, A
    Kneitz, C
    Palanichamy, A
    Dörner, T
    Tony, HP
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) : R714 - R724
  • [35] Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
    Anne-Sophie Rouzière
    Christian Kneitz
    Arumugam Palanichamy
    Thomas Dörner
    Hans-Peter Tony
    Arthritis Research & Therapy, 7
  • [36] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [37] Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab
    Assayag, Franck
    Brousse, Nicole
    Couturier, Jerome
    Macintyre, Elizabeth
    Mathiot, Claire
    Dewulf, Sebastien
    Froget, Benoit
    Vincent-Salomon, Anne
    Decaudin, Didier
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (06) : 387 - 388
  • [38] Intratesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases
    Kerl, K.
    Prins, C.
    Saurat, J. H.
    French, L. E.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (06) : 1197 - 1200
  • [39] Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with Rituximab, a chimeric Anti-CD20 monoclonal antibody
    Soda, R
    Costanzo, A
    Cantonetti, M
    Orlandi, A
    Bianchi, L
    Chimenti, S
    ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 207 - 208
  • [40] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 285B - 285B
12345